Evidence map›Paper›PMID 39162326›Full record

ArticleThe Laryngoscope2025

Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.

Lauran K Evans, Haidee Chen, Manwel Taki Labib, D Alexander Cronkite, Alice C Yu, Maya Ashendouek, David Elashoff, Wanxing Chai-Ho, Deborah J Wong, Maie St John

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. The efficacy of various treatment modalities and their combinations in improving survival outcomes for anaplastic thyroid cancer: a systematic review and network meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lauran K EvansDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0002-9860-5248
Haidee ChenDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Manwel Taki LabibDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
D Alexander CronkiteDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Alice C YuDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Maya AshendouekDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
David ElashoffDepartment of Biostatistics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Wanxing Chai-HoDepartment of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Deborah J WongDepartment of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Maie St JohnDepartment of Head and Neck Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0001-7068-9534

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Enabling careers as surgeon-scientists in otolaryngology-head and neck surgeryR25DC020151 · NIDCD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Jennifer L Long · 2022 to 2026
$887k
NCI NIH HHS P30 CA016042NIDCD NIH HHS R25 DC020151NIDCD NIH HHS R25DC020151
6 · The paper itself

Abstract

objectivesAnaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC-targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC.

methodsA single-tertiary-institution chart review of patients diagnosed with advanced-stage ATC, and who underwent surgery as part of their treatment, was performed between 2000 and 2023, with 41 patients included. Demographics, clinical characteristics, and survival data were collected and analyzed via Kaplan-Meier and Cox proportional hazards analyses.

results54% of patients were female, and average age was 67.4 years old. The most common mutations identified were BRAF (15 patients), p53 (9 patients), and p63 (2 patients). A total of 18 patients utilized targeted or immunotherapy, with Trametinib and Dabrafenib (9 patients) as the most common agents used. Two-year overall survival was 24%, and 5-year overall survival was 23%, with median survival time of 7.6 months. Kaplan-Meier analysis demonstrated improved survival in patients who received chemotherapy (p = 0.048). Cox proportional hazards analysis demonstrated that patients treated with immunotherapy or targeted therapy had a statistically significant increase in survival compared with patients who did not receive these therapies (p = 0.016). Additionally, females and those with a p63 mutation demonstrated improved survival outcomes (p = 0.010, p = 0.001).

conclusionsTargeted therapy and immunotherapy use should be strongly considered when treating patients with ATC. Further studies into novel drugs targeting immune checkpoints and combination therapy are needed to better optimize treatment of patients with ATC. LEVEL OF EVIDENCE: 3 Laryngoscope, 135:478-484, 2025.

Indexed as

Thyroid Carcinoma, AnaplasticThyroid NeoplasmsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansImidazolesImmunotherapyKaplan-Meier EstimateMaleMiddle AgedMolecular Targeted TherapyMutationNeoplasm StagingOximesBRAF protein, humandabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonesTP63 protein, humantrametinibTranscription FactorsTumor Suppressor Protein p53Tumor Suppressor Proteinsanaplastic thyroid cancerATCimmunotherapysystemic therapytargeted therapythyroid

Identifiers

PMID39162326
PMCPMC11635144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.